Martin Strebl-Bantillo is an Associate Principal at Clarion. He has extensive expertise in primary market research and strategy development to support new product commercialization across a range of therapeutic areas, with a focus on oncology and transplant care.
Prior to joining Clarion, Martin received his PhD in Chemistry & Chemical Biology from Harvard University, and completed a postdoctoral fellowship in Neuroimaging at MGH/Harvard Medical School. His research focused on chemical methodology of introducing radioactive labels into small molecules, and the applications of his technology in PET-based visualization of epigenetic enzymes in the living brain.
Martin completed his BSc in Chemistry and Biochemistry from LMU Munich in his native Germany.
Current role